12/09/2022 (Agence Europe) – The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) announced on Monday 12 September that it has recommended to the European Commission the authorisation of a bivalent mRNA vaccine developed by Pfizer-BioNTech that targets the SARS-CoV-2 sub-variants of concern BA.4 and BA.5 (Omicron) as well as the original SARS-CoV-2 coronavirus strain (see EUROPE 13012/23). The administration of this ‘Comirnaty’ vaccine is recommended for adults aged 12 years and older who have already completed a first vaccination course against SARS-CoV-2. The European strategy is to develop a broad set of vaccines adapted to different SARS-CoV-2 variants of concern so that Member States have several options to tailor their vaccination campaign. Two bivalent vaccines targeting BA.1 and the original SARS-CoV-2 strain received conditional market authorisation on 1 September (see EUROPE 13013/14). (EV)